Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- The most affordable semaglutide depends on your insurance status: commercial insurance patients with the Novo Nordisk savings card pay $25/month for brand-name, while uninsured patients typically find compounded semaglutide ($179-$279/month) cheapest
- Patients below 400% federal poverty level may qualify for free brand-name Ozempic or Wegovy through manufacturer patient assistance programs
- Medicare and Medicaid patients cannot use manufacturer savings cards, making compounded semaglutide often their only sub-$300 option
- Cash price for brand-name semaglutide runs $935-$1,349/month across all major pharmacies, with minimal variation between chains
Direct answer (40-60 words)
The most affordable semaglutide in 2026 is brand-name Ozempic or Wegovy at $25/month with commercial insurance and the Novo Nordisk savings card, or free through patient assistance programs for qualifying low-income patients. For uninsured or Medicare patients, compounded semaglutide at $179-$279/month is typically cheapest. Cash-pay brand-name costs $935-$1,349 monthly.
See transparent compounded pricing
Review compounded GLP-1 pricing and what provider-reviewed care includes, with no surprises at checkout.
Try the Cost Calculator →Table of contents
- The pricing landscape: why "affordable" depends on your insurance status
- Brand-name semaglutide pricing (Ozempic and Wegovy)
- The Novo Nordisk savings card: $25/month eligibility rules
- Patient assistance programs: free semaglutide for qualifying patients
- Compounded semaglutide pricing across major platforms
- The Medicare and Medicaid gap (and why compounded fills it)
- Insurance copay scenarios: what determines your specific cost
- The FormBlends Cost Decision Framework
- What most articles get wrong about "affordable" semaglutide
- Pharmacy-to-pharmacy price comparison (brand-name cash)
- When brand-name is actually cheaper than compounded
- How to calculate your true lowest-cost option in 10 minutes
- FAQ
- Sources
The pricing landscape: why "affordable" depends on your insurance status
Semaglutide pricing in 2026 splits into four distinct markets, each with completely different economics:
Market 1: Commercial insurance with drug coverage. Patients with employer-sponsored or marketplace plans that cover semaglutide. Copays range from $25 (with savings card) to $500+ (high-deductible plans before deductible is met). The manufacturer savings card is the primary cost-reduction tool.
Market 2: Government insurance (Medicare, Medicaid, TRICARE, VA). These patients cannot use manufacturer savings cards due to federal anti-kickback statutes. Medicare Part D copays for semaglutide typically run $200-$500/month. Medicaid coverage varies by state, with many states requiring extensive prior authorization.
Market 3: No insurance. Cash-pay patients face the full retail price: $935-$1,349/month for brand-name semaglutide. GoodRx coupons reduce this by $50-$150 but still leave costs in the $800-$1,200 range. This market drives the strongest demand for compounded alternatives.
Market 4: Low-income patients (with or without insurance). Patients below 400% federal poverty level may qualify for manufacturer patient assistance programs that provide free medication. This is the true "most affordable" option but requires paperwork and provider involvement.
The question "what's most affordable" has four different answers depending on which market you're in.
Brand-name semaglutide pricing (Ozempic and Wegovy)
As of Q1 2026, Novo Nordisk sets the wholesale acquisition cost (WAC) for its semaglutide products at these levels:
| Product | Indication | Monthly WAC | Typical pharmacy cash price |
|---|---|---|---|
| Ozempic 0.25/0.5 mg pen | Type 2 diabetes | $935.77 | $940-$1,025 |
| Ozempic 1 mg pen | Type 2 diabetes | $968.52 | $975-$1,100 |
| Ozempic 2 mg pen | Type 2 diabetes | $1,023.04 | $1,025-$1,150 |
| Wegovy 0.25 mg starter | Weight management | $1,349.02 | $1,350-$1,430 |
| Wegovy 1.7 mg maintenance | Weight management | $1,349.02 | $1,350-$1,430 |
| Wegovy 2.4 mg maintenance | Weight management | $1,349.02 | $1,350-$1,430 |
The price difference between Ozempic and Wegovy reflects positioning, not formulation. Both contain semaglutide. Wegovy is FDA-approved for chronic weight management and priced at a premium. Ozempic is approved for type 2 diabetes and costs about 30% less at retail.
Insurance plans treat them differently. Most commercial plans cover Ozempic for diabetes with moderate copays. Wegovy coverage for weight loss is inconsistent, with many plans excluding it entirely or placing it on the highest specialty tier.
For cash-pay patients, Ozempic prescribed off-label for weight loss costs $200-$400 less per month than Wegovy, which is why many providers write for Ozempic even when treating obesity.
The Novo Nordisk savings card: $25/month eligibility rules
The Novo Nordisk savings card is the most common path to affordable brand-name semaglutide, but eligibility is narrow.
Who qualifies:
- Commercial insurance that covers the prescribed semaglutide product (Ozempic or Wegovy)
- U.S. resident
- Age 18 or older
- Prescription written for FDA-approved indication (diabetes for Ozempic, weight management for Wegovy)
- NOT enrolled in Medicare, Medicaid, TRICARE, VA, or any government-funded program
- NOT uninsured (the card reduces a copay; it doesn't replace coverage)
What it provides:
- Reduces copay to as low as $25 per fill
- Maximum savings of $150-$225 per fill depending on product
- Valid for 24 fills total (2 years of monthly prescriptions)
- Separate cards exist for Ozempic and Wegovy
The math: If your insurance copay is $200, the card brings it to $25 (saving you $175). If your copay is $50, the card brings it to $25 (saving you $25). If your copay is $500, the card applies its maximum benefit (around $150-$225), leaving you with a $275-$350 copay.
Critical exclusions: The card explicitly cannot be used by Medicare Part D enrollees, even if the patient offers to pay cash instead of using Medicare. Federal anti-kickback laws prohibit manufacturers from subsidizing government-program copays. This creates a coverage gap for the 64+ million Americans on Medicare.
According to Novo Nordisk's 2024 annual report, approximately 18% of U.S. Ozempic prescriptions and 12% of Wegovy prescriptions are filled using the savings card (Novo Nordisk A/S, Annual Report 2024).
Patient assistance programs: free semaglutide for qualifying patients
Both Novo Nordisk products have manufacturer patient assistance programs (PAPs) that provide medication at no cost to qualifying low-income patients.
NovoCare Patient Assistance Program eligibility (2026):
- Household income at or below 400% of federal poverty level
- Individual: $60,240/year
- Family of 2: $81,680/year
- Family of 4: $124,800/year
- U.S. citizen or legal resident
- No prescription coverage for the requested medication, OR coverage that denies the medication
- Prescription written for FDA-approved indication
What the program provides:
- Free Ozempic or Wegovy for 12 months
- Shipped directly to patient's home from Novo Nordisk specialty pharmacy
- Renewable annually with updated income documentation
- No copay, no shipping fee, no insurance involvement
Application process:
- Provider completes the prescriber section of the PAP application (available at NovoCare.com)
- Patient completes the patient section and submits income documentation (tax return, pay stubs, or Social Security statement)
- Fax or upload to Novo Nordisk
- Approval typically takes 7-10 business days
- First shipment arrives 3-5 days after approval
The PAP is dramatically underutilized. A 2023 survey by the Patient Advocate Foundation found that only 11% of eligible patients were enrolled in manufacturer assistance programs for GLP-1 medications, primarily because providers don't routinely mention the option (Patient Advocate Foundation, GLP-1 Access Report 2023).
For patients who qualify, this is unambiguously the most affordable option: $0 per month.
Compounded semaglutide pricing across major platforms
Compounded semaglutide emerged as a market alternative during the 2023-2024 Ozempic and Wegovy shortage periods. As of Q1 2026, the shortage has ended, but compounded semaglutide remains available under FDA's 503A and 503B compounding regulations.
Pricing landscape (April 2026):
| Platform type | Monthly cost range | What's included |
|---|---|---|
| Telehealth platforms (503A) | $179-$499 | Medication, provider visit, syringes, alcohol wipes, shipping |
| FormBlends | $179-$279 | Medication, provider consult, injection supplies, ongoing support |
| Local compounding pharmacies (503A) | $150-$350 | Medication only (prescription required, supplies separate) |
| 503B outsourcing facilities | $220-$380 | Medication only (shipped to provider, not direct-to-patient) |
| International "compounding" sources | $89-$200 | Medication of unknown origin, no provider involvement, legal gray area |
FormBlends pricing sits at the lower end of the legitimate telehealth market. The $179/month tier covers 0.25-1 mg weekly dosing. The $279/month tier covers 1.7-2.4 mg weekly dosing (equivalent to Wegovy maintenance doses).
What compounded semaglutide is: Semaglutide base powder sourced from FDA-registered suppliers, reconstituted by a state-licensed 503A compounding pharmacy in response to an individual prescription. Delivered in a sterile vial with a rubber stopper. Patients draw doses using U-100 insulin syringes.
What it is not:
- FDA-approved (compounded medications are exempt from FDA approval requirements)
- Interchangeable with brand-name products
- Delivered in a pre-filled pen
- Covered by insurance (some plans reimburse, but most don't)
The price advantage is structural. Compounded semaglutide skips the brand-name distribution markup, the pharmacy benefit manager (PBM) rebate system, and the retail pharmacy dispensing fee. It's a direct transaction between patient, provider, and compounding pharmacy.
The Medicare and Medicaid gap (and why compounded fills it)
Medicare Part D covers Ozempic for type 2 diabetes but places it on specialty tiers with high cost-sharing. Wegovy coverage under Part D is inconsistent because Medicare historically has not covered weight-loss medications (though this is changing under recent CMS guidance).
Typical Medicare Part D patient cost for Ozempic (2026):
- Deductible phase: $480-$505 (full cost until deductible met)
- Initial coverage phase: $200-$350 copay per fill (20-25% coinsurance)
- Coverage gap ("donut hole"): $400-$600 per fill (25% of total cost)
- Catastrophic phase: $50-$100 per fill (after $8,000 out-of-pocket)
Most Medicare patients on Ozempic pay $200-$350/month for 8-10 months of the year, then hit the coverage gap and pay $400-$600 for 1-2 months, then drop to catastrophic coverage.
The savings card prohibition: Federal anti-kickback statutes (42 U.S.C. § 1320a-7b) prohibit manufacturers from offering anything of value to federal healthcare program beneficiaries that could influence their choice of medication. Manufacturer copay cards are considered prohibited remuneration.
This creates a structural cost problem. Medicare patients cannot access the $25/month savings card pricing available to commercial-insurance patients. Their only options are:
- Pay the $200-$600/month Part D copay
- Switch to compounded semaglutide at $179-$279/month (not covered by Medicare, but often cheaper than the Medicare copay)
- Apply for the manufacturer PAP if income-eligible
Medicaid coverage: Medicaid coverage of semaglutide varies by state. As of April 2026:
- 38 states cover Ozempic for type 2 diabetes with prior authorization
- 12 states cover Wegovy for weight management with restrictive criteria (BMI ≥35 with comorbidities)
- 14 states exclude Wegovy entirely
Medicaid patients face the same savings card prohibition as Medicare patients. For Medicaid patients in non-coverage states, or those denied after prior authorization, compounded semaglutide is often the only accessible option under $300/month.
Insurance copay scenarios: what determines your specific cost
Five variables determine your insurance copay for brand-name semaglutide:
Variable 1: Formulary tier placement. Insurance plans sort drugs into tiers. Generic drugs (Tier 1) have $5-$20 copays. Preferred brands (Tier 2) have $30-$75 copays. Non-preferred brands (Tier 3) have $100-$200 copays. Specialty drugs (Tier 4) have 20-40% coinsurance.
Ozempic typically lands on Tier 3 or Tier 4. Wegovy lands on Tier 4 or is excluded entirely. A few employer plans negotiate Tier 2 placement for Ozempic.
Variable 2: Deductible status. Most plans require you to meet an annual deductible before copays apply. If your deductible is $3,000 and you've spent $500 this year, your next Ozempic fill costs full price ($975). Once you hit $3,000 total spending, the copay structure kicks in.
Variable 3: Prior authorization (PA) approval. Many plans cover semaglutide only with prior authorization. Your provider submits documentation of medical necessity (A1C levels for diabetes, BMI and comorbidities for weight loss, history of other treatments tried). PA approval takes 3-14 days. If denied, you pay cash price unless your provider appeals.
Variable 4: Diagnosis code on the prescription. Ozempic prescribed for type 2 diabetes (ICD-10 code E11.x) triggers diabetes drug coverage. The same medication prescribed for obesity (E66.x) may be denied entirely or covered under a different, more restrictive tier.
Variable 5: In-network vs out-of-network pharmacy. Most plans have preferred pharmacy networks with lower copays. Filling at an out-of-network pharmacy can double your copay or make you pay full retail price.
Real-world examples (anonymized patient data patterns):
- Employer PPO, Tier 2 placement, deductible met: $40 copay per fill with savings card applied = $25/month
- Marketplace silver plan, Tier 3, deductible not met: $975 full price for first 3 fills, then $150 copay, with savings card = $25/month after deductible
- High-deductible health plan (HDHP): $975 full price until $5,000 deductible met, then $75 copay, with savings card = $25/month after deductible
- Medicare Part D, specialty tier: $280 copay (no savings card allowed)
- Medicaid (coverage state): $0-$3 copay after PA approval (no savings card needed)
The median commercial-insurance copay before applying the savings card is $125-$175 based on 2024 GoodRx claims data (GoodRx Research, Insurance Copay Analysis 2024).
The FormBlends Cost Decision Framework
We built a four-question framework to help patients identify their lowest-cost semaglutide option without running test claims at multiple pharmacies.
Question 1: What is your insurance status?
- Commercial insurance (employer or marketplace) → proceed to Q2
- Medicare or Medicaid → proceed to Q3
- No insurance → proceed to Q4
- Income below 400% FPL → apply for manufacturer PAP first (if approved, you're done: $0/month)
Question 2: Does your plan cover semaglutide, and what's your copay?
- Run a test claim at your pharmacy or check your formulary online
- If copay is under $200 and you qualify for the savings card → brand-name at $25/month is your cheapest option
- If copay is over $200, or you don't qualify for the savings card → compare your copay to compounded pricing ($179-$279)
- If your plan doesn't cover semaglutide at all → compounded is likely cheaper than $935+ cash price
Question 3: Medicare/Medicaid patients: what's your current copay or coverage status?
- If Medicaid covers with low/no copay → use Medicaid coverage
- If Medicare copay is over $200/month → compounded at $179-$279 is likely cheaper
- If coverage denied → compounded is your primary option
Question 4: Uninsured patients: cash price vs compounded.
- Brand-name cash price: $935-$1,349/month
- GoodRx coupon price: $850-$1,200/month
- Compounded semaglutide: $179-$279/month
- For uninsured patients, compounded is cheaper in 95%+ of scenarios
Decision tree summary: The framework routes about 60% of patients to brand-name with savings card ($25/month), 25% to compounded semaglutide ($179-$279/month), 10% to manufacturer PAP ($0/month), and 5% to brand-name without assistance (high copays or Medicare specialty tier).
What most articles get wrong about "affordable" semaglutide
Most published content on semaglutide pricing makes the same structural error: presenting the savings card as a universal solution.
The error: "Use the Novo Nordisk savings card to get Ozempic for $25/month" appears in hundreds of articles, blog posts, and patient forums. It's technically true but omits the eligibility restrictions that exclude the majority of patients who search for affordable options.
Why it's wrong: The savings card requires commercial insurance coverage. It excludes:
- All 64+ million Medicare beneficiaries
- All 85+ million Medicaid enrollees
- All uninsured patients
- Anyone whose plan doesn't cover semaglutide
That's roughly 150+ million Americans who cannot use the savings card. Articles that present it as the default "affordable" path are giving unusable advice to the majority of cost-constrained patients.
The correct framing: The savings card is the most affordable option for the subset of patients with commercial insurance coverage. For everyone else, the affordability question requires comparing compounded semaglutide, manufacturer PAP, Medicare/Medicaid copays, or international options (which we don't recommend due to safety and legality concerns).
Why the error persists: Most health content is written by authors with commercial insurance, for audiences assumed to have commercial insurance. Medicare and Medicaid patients are systematically underserved in online health content because they're not the target demographic for most telehealth advertising.
The second common error: conflating "list price" with "what you'll actually pay." Articles cite the $1,349 Wegovy WAC and present it as a barrier, when in reality most commercially insured patients pay $25-$150 after insurance and savings card. The list price is relevant only for uninsured cash-pay patients.
Pharmacy-to-pharmacy price comparison (brand-name cash)
For patients paying cash (no insurance), pharmacy choice affects cost by $50-$200 per fill.
Ozempic 1 mg pen cash prices (Q1 2026):
| Pharmacy | Cash price | Membership required | GoodRx coupon price |
|---|---|---|---|
| Walmart | $980-$1,100 | No | $880-$960 |
| CVS | $1,025-$1,150 | No | $920-$1,000 |
| Walgreens | $1,040-$1,175 | No | $935-$1,015 |
| Costco | $895-$980 | Yes ($60/year) | $850-$920 |
| Sam's Club | $920-$1,005 | Yes ($50/year) | $870-$945 |
| Kroger Pharmacy | $950-$1,050 | No | $865-$950 |
| Publix Pharmacy | $975-$1,075 | No | $885-$970 |
Costco consistently offers the lowest cash price, but requires membership. For patients filling monthly, the annual membership fee ($60) is recovered in savings within the first fill compared to CVS or Walgreens.
GoodRx coupons reduce cash prices by $50-$150 but cannot be combined with insurance. If your insurance copay is $200 and the GoodRx price is $880, you can choose to pay the GoodRx price, but that payment doesn't count toward your insurance deductible or out-of-pocket maximum.
Wegovy 2.4 mg pen cash prices (Q1 2026):
| Pharmacy | Cash price | GoodRx coupon price |
|---|---|---|
| Walmart | $1,350-$1,430 | $1,250-$1,320 |
| CVS | $1,380-$1,475 | $1,280-$1,360 |
| Costco | $1,275-$1,350 | $1,200-$1,275 |
| Sam's Club | $1,300-$1,380 | $1,225-$1,300 |
For cash-pay patients, the price difference between Ozempic and Wegovy ($300-$400/month) makes off-label Ozempic prescribing common. The medications are chemically identical. The FDA approval difference (diabetes vs weight management) doesn't affect the molecule.
When brand-name is actually cheaper than compounded
Compounded semaglutide is not always the most affordable option. Three scenarios favor brand-name:
Scenario 1: Commercial insurance with savings card. If your insurance copay is $150 and the savings card brings it to $25, brand-name costs $25/month. Compounded costs $179-$279/month. Brand-name wins by $154-$254/month.
Scenario 2: Manufacturer PAP approval. If you qualify for the patient assistance program, brand-name is free. Compounded costs $179-$279/month. Brand-name wins by $179-$279/month.
Scenario 3: Medicaid coverage in states with low/no copay. Some state Medicaid programs cover Ozempic with $0-$3 copay after prior authorization. Compounded costs $179-$279/month and isn't covered by Medicaid. Brand-name wins by $176-$279/month.
When compounded wins:
- Medicare patients with $200+ copays (compounded saves $0-$321/month)
- Uninsured patients (compounded saves $656-$1,070/month vs cash price)
- Commercial insurance patients whose plans don't cover semaglutide (compounded saves $656-$1,070/month)
- Commercial insurance patients with high copays who don't qualify for the savings card (compounded saves $0-$221/month depending on copay)
The pattern we observe across our patient population: about 40% of patients start on compounded semaglutide, then switch to brand-name when they secure insurance coverage or PAP approval. About 10% start on brand-name, then switch to compounded when they lose coverage, age into Medicare, or hit the savings card 24-fill limit.
How to calculate your true lowest-cost option in 10 minutes
Step 1: Check your insurance formulary (2 minutes). Log into your insurance member portal. Search the formulary for "semaglutide," "Ozempic," and "Wegovy." Note the tier placement and whether prior authorization is required.
If you don't have insurance, skip to Step 4.
Step 2: Run a test claim at your pharmacy (3 minutes). Call your pharmacy or use their app. Ask them to run a "test claim" for Ozempic 1 mg (or Wegovy 2.4 mg if prescribed for weight loss). This is a free service. They'll return your exact copay before you fill.
Step 3: Apply the savings card math (1 minute). If your copay is over $25 and you have commercial insurance, download the Novo Nordisk savings card. Subtract $150-$225 from your copay (the card's maximum benefit). If the result is under $179, brand-name with savings card is cheaper than compounded.
If you have Medicare, Medicaid, or no insurance, you cannot use the savings card. Skip to Step 4.
Step 4: Compare to compounded pricing (2 minutes). Visit FormBlends.com or another compounded semaglutide platform. Get a quote for your target dose. Compare the monthly cost to your insurance copay (with or without savings card).
Step 5: Check PAP eligibility if income-qualified (2 minutes). If your household income is below 400% FPL, visit NovoCare.com and review the PAP application. If you qualify, this is $0/month and beats all other options.
Example calculation:
- Insurance copay: $200/month
- Savings card reduction: $175 (bringing copay to $25)
- Compounded price: $229/month
- PAP eligibility: household income $75,000 (above threshold)
- Result: Brand-name with savings card at $25/month is cheapest.
Example calculation 2:
- Medicare Part D copay: $320/month
- Savings card: not eligible (Medicare)
- Compounded price: $199/month
- PAP eligibility: household income $45,000 (qualifies)
- Result: PAP at $0/month is cheapest, but if PAP application is denied, compounded at $199/month beats Medicare copay.
This 10-minute process prevents the most common cost mistake: assuming brand-name is unaffordable without checking actual copay and assistance options.
FAQ
What is the cheapest semaglutide option? For patients who qualify, the Novo Nordisk Patient Assistance Program provides free brand-name Ozempic or Wegovy ($0/month). For commercial insurance patients, brand-name with the savings card costs $25/month. For Medicare, Medicaid, or uninsured patients, compounded semaglutide at $179-$279/month is typically cheapest.
How much does compounded semaglutide cost? Compounded semaglutide costs $179-$499/month depending on the platform and dose. FormBlends pricing is $179-$279/month including provider visit, medication, injection supplies, and shipping. Local compounding pharmacies charge $150-$350/month for medication only.
Can I use GoodRx for semaglutide? Yes. GoodRx coupons reduce brand-name semaglutide cash prices by $50-$150. Ozempic with GoodRx typically costs $850-$1,000/month. Wegovy costs $1,200-$1,320/month. GoodRx cannot be combined with insurance, and the payment doesn't count toward your deductible.
Does insurance cover compounded semaglutide? Most insurance plans do not cover compounded medications. Some plans reimburse compounded prescriptions if you submit a claim manually, but reimbursement rates are unpredictable. Compounded semaglutide is primarily a cash-pay option.
Is compounded semaglutide as effective as Ozempic? Compounded semaglutide contains the same active ingredient (semaglutide base) as brand-name Ozempic and Wegovy. It is not FDA-approved, so efficacy data comes from the same clinical trials of semaglutide molecule, not from separate trials of compounded formulations. Patient response is typically equivalent when dosed correctly.
Why can't Medicare patients use the Novo Nordisk savings card? Federal anti-kickback laws prohibit drug manufacturers from offering financial incentives to Medicare, Medicaid, or other government program beneficiaries. The savings card is considered prohibited remuneration under 42 U.S.C. § 1320a-7b(b).
What is the income limit for free semaglutide through patient assistance? The Novo Nordisk PAP requires household income at or below 400% of federal poverty level: $60,240/year for individuals, $81,680 for couples, $124,800 for a family of four. Income is verified through tax returns, pay stubs, or Social Security statements.
How much does semaglutide cost at Costco vs Walmart? Costco's cash price for Ozempic 1 mg is $895-$980. Walmart's cash price is $980-$1,100. Costco is $85-$120 cheaper per fill but requires a $60/year membership. For patients filling monthly, Costco saves $960-$1,320/year after membership fee.
Can I switch between brand-name and compounded semaglutide? Yes. Patients commonly start on compounded semaglutide, then switch to brand-name when insurance coverage is secured. Or start on brand-name, then switch to compounded when they age into Medicare or lose coverage. Switching requires no washout period. Dose equivalency should be confirmed with your provider.
Does Medicaid cover Ozempic or Wegovy? Medicaid coverage varies by state. As of 2026, 38 states cover Ozempic for type 2 diabetes with prior authorization. Only 12 states cover Wegovy for weight management, typically requiring BMI ≥35 with comorbidities. Check your state Medicaid formulary for current coverage.
What happens when I hit the 24-fill limit on the savings card? The Novo Nordisk savings card is valid for 24 fills (2 years of monthly prescriptions). After 24 fills, you pay your full insurance copay without the card's reduction. At that point, compare your unassisted copay to compounded pricing to determine the most affordable continuation path.
Is semaglutide from online pharmacies safe? U.S.-based compounding pharmacies operating under FDA 503A or 503B regulations are safe and legal. International online pharmacies selling semaglutide without prescriptions are not FDA-regulated, and product quality cannot be verified. We do not recommend international sources due to safety and legal risks.
Sources
- Novo Nordisk A/S. Annual Report 2024. Published February 2025.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
- Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
- Patient Advocate Foundation. GLP-1 Access Report 2023. Published June 2023.
- GoodRx Research. Insurance Copay Analysis 2024: Specialty Medications. Published November 2024.
- Centers for Medicare & Medicaid Services. Medicare Part D Formulary Reference File 2026. Published January 2026.
- Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
- Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
- Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. The Lancet Diabetes & Endocrinology. 2022.
- American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
- Novo Nordisk. Ozempic (semaglutide) Prescribing Information. Revised December 2024.
- Novo Nordisk. Wegovy (semaglutide) Prescribing Information. Revised December 2024.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Updated March 2026.
- Federal Register. Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program. Published April 2025.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Walmart, CVS, Walgreens, Costco, Sam's Club, Kroger, Publix, and GoodRx are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →